Current Report Filing (8-k)
16 May 2020 - 2:34AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):May 15, 2020
One
World Pharma, Inc.
(Exact
name of registrant as specified in charter)
Nevada
|
|
333-200529
|
|
61-1744826
|
(State
or other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
3471
West Oquendo Road, Suite 301 Las Vegas, NV
|
|
89118
|
(Address
of principal executive offices)
|
|
(zip
code)
|
Registrant’s
telephone number, including area code: (800) 605-3201
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Section
8 – Other Events
Item
8.01 Other Events.
Inability
to file Annual Report on Form 10-Q for the period ended March 31, 2020 in a timely manner due to circumstances related to COVID-19
global pandemic.
One
World Pharma, Inc. is unable to file its March 31, 2020 Quarterly Report on Form 10-Q by the original deadline of May 15, 2020
due to circumstances related to the global impact of COVID-19. Our key personnel have been distracted by other priorities associated
with workplace closures, school closures, and stay at home orders. Our work efficiencies have been negatively impacted.
We
are relying on the SEC order dated March 25, 2020 (Release No. 34-88465, which supersedes the SEC’s order dated March 4,
2020 (Release No. 34-88318) to extend the due date for the filing of our Form 10-Q until June 29, 2020 (45 days after the original
due date). We will work diligently to comply with such requirement, and, at this time, management believes that it may need the
entire available extension period.
Additional
risk factor disclosure
The
following is a risk factor applicable to us relating to the global COVID-19 pandemic.
We
rely on professionals all over the United States and in Colombia, which are impacted by the global pandemic, causing our resources
to be affected. Our business operations have been and may continue to be materially and adversely affected by the COVID-19 pandemic.
An
outbreak of respiratory illness caused by COVID-19 emerged in Wuhan city, Hubei province, PRC, in late 2019 and has been expanding
globally. COVID-19 is considered to be highly contagious and poses a serious public health threat.
Restrictive
measures have been imposed in major cities in the USA, including Los Angeles, New York, and Las Vegas, and throughout the world
in an effort to contain the COVID-19 outbreak. The World Health Organization (the “WHO”) is closely monitoring and
evaluating the situation. On March 11, 2020, the WHO declared the outbreak of COVID-19 a pandemic, expanding its assessment of
the threat beyond the global health emergency it had announced in January.
In
the first quarter of 2020, the COVID-19 outbreak has caused disruptions in our operations, which have resulted in delays on existing
projects. A prolonged disruption or any further unforeseen delay in our operations could continue to result in increased costs
and reduced, or delayed revenue.
If
the outbreak of COVID-19 is not effectively and timely controlled, our business operations and financial condition may be materially
and adversely affected as a result of the deteriorating market outlook for sales, the slowdown in regional and national economic
growth, weakened liquidity and financial condition of our customers and vendors or other factors that we cannot foresee. Any of
these factors and other factors beyond our control could have an adverse effect on the overall business environment, cause uncertainties,
cause our business to suffer in ways that we cannot predict and materially and adversely impact our business, financial condition
and results of operations.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
One
World Pharma, Inc.
|
|
|
|
Date: May 15, 2020
|
|
|
|
|
By:
|
/s/
Craig Ellins
|
|
|
Craig
Ellins
|
|
|
Chief
Executive Officer
|
One World Products (QB) (USOTC:OWPC)
Historical Stock Chart
From Jun 2024 to Jul 2024
One World Products (QB) (USOTC:OWPC)
Historical Stock Chart
From Jul 2023 to Jul 2024